Cargando…

Glucagon-Like Peptide-1 and Diabetes 2012

Detalles Bibliográficos
Autores principales:	Monami, Matteo, Di Pasquale, Giovanni, Rowzee, Anna, Rotella, Carlo Maria, Mannucci, Edoardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566481/ https://www.ncbi.nlm.nih.gov/pubmed/23431286 http://dx.doi.org/10.1155/2012/768760

Ejemplares similares

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
por: Mossello, Enrico, et al.
Publicado: (2011)

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
por: Monami, Matteo, et al.
Publicado: (2011)

Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials
por: Mannucci, Edoardo, et al.
Publicado: (2016)

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
por: Uccellatore, Annachiara, et al.
Publicado: (2015)

Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future
por: Maria Rotella, Carlo, et al.
Publicado: (2013)

Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
por: Veneti, Stavroula, et al.
Publicado: (2020)

Adipokines as Possible New Predictors of Cardiovascular Diseases: A Case Control Study
por: Pala, Laura, et al.
Publicado: (2012)

Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
por: Monami, Matteo, et al.
Publicado: (2011)

Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
por: Mannucci, Edoardo, et al.
Publicado: (2010)

Saturation of critical care capacity and mortality in patients with the novel coronavirus (COVID-19) in Italy
por: Mannucci, Edoardo, et al.
Publicado: (2020)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Glucagon and heart in type 2 diabetes: new perspectives
por: Ceriello, Antonio, et al.
Publicado: (2016)

Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering
por: Jacob, Jubbin Jagan, et al.
Publicado: (2021)

Autologous Peripheral Blood Mononuclear Cells in Patients with Small Artery Disease and Diabetic Foot Ulcers: Efficacy, Safety, and Economic Evaluation
por: Ragghianti, Benedetta, et al.
Publicado: (2023)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
por: Michel, Martin C., et al.
Publicado: (2008)

Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies
por: Silverii, Giovanni Antonio, et al.
Publicado: (2021)

Correction to: Glucose control in diabetes during home confinement for the first pandemic wave of COVID‑19: a meta‑analysis of observational studies
por: Silverii, Giovanni Antonio, et al.
Publicado: (2021)

Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment?
por: Hamasaki, Hidetaka
Publicado: (2018)

Factors associated with increased all-cause mortality during the COVID-19 pandemic in Italy
por: Mannucci, Edoardo, et al.
Publicado: (2020)

Potential Impact of Climate on Novel Corona Virus (COVID-19) Epidemic
por: Monami, Matteo, et al.
Publicado: (2020)

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2011)

Bone: Incretin Hormones Perceiver or Receiver?
por: Dicembrini, Ilaria, et al.
Publicado: (2012)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
por: Lisco, Giuseppe, et al.
Publicado: (2023)

Psychopathology and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes
por: Rotella, Francesco, et al.
Publicado: (2013)

Pulse Pressure and Prediction of Incident Foot Ulcers in Type 2 Diabetes
por: Monami, Matteo, et al.
Publicado: (2009)

New concept of the glucagon‐like peptide‐1 signaling pathway on pancreatic insulin secretion
por: Kaku, Kohei
Publicado: (2019)

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?
por: Bloomgarden, Zachary
Publicado: (2023)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Sars-CoV2 vaccine hesitancy in Italy: A survey on subjects with diabetes
por: Scoccimarro, Daniele, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Rosiglitazone and Risk of Cancer: A meta-analysis of randomized clinical trials
por: Monami, Matteo, et al.
Publicado: (2008)

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A meta-analysis of randomized clinical trials
por: Monami, Matteo, et al.
Publicado: (2011)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_klemq44ogt7g3nrqt0hujgnenu